Sanofi (SAN.PA)

Paris - Paris Delayed Price. Currency in EUR
67.64-0.39 (-0.57%)
At close: 11:35 AM EDT
People also watch:
Interactive chart
  • 1d
  • 5d
  • 1m
  • 6m
  • YTD
  • 1y
  • 2y
  • 5y
  • 10y
  • Max
Prev Close68.03
Bid71.12 x 1000
Ask71.74 x 44000
Day's Range66.72 - 67.91
52wk Range24.83 - 93.82
1y Target EstN/A
Market Cap86.02B
P/E Ratio (ttm)21.03
Avg Vol (3m)9,164
Dividend & YieldN/A (N/A)
Earnings DateN/A
  • Reuters10 hours ago

    Regeneron eczema drug reduces itch and anxiety, two studies show

    Patients taking an experimental eczema drug from Regeneron Pharmaceuticals Inc and Sanofi Inc experienced significant relief in itching and in anxiety and depression symptoms, meeting secondary goals of two large studies, researchers said on Saturday. Regeneron and Sanofi recently asked U.S. regulators to approve the injectable medicine, Dupixent (dupilumab), after it significantly cleared skin lesions in the same pair of studies without serious side effects typically seen with standard treatments for the chronic inflammatory skin disease. "Reduction of itch intensity is important because itching is one of the most burdensome symptoms for patients and can impact other aspects of their lives, such as sleep," said Dr. Eric Simpson, a dermatologist at Oregon Health & Science University who led the trials.

  • PR Newswire10 hours ago

    Regeneron and Sanofi Announce Positive Dupixent® (dupilumab) Phase 3 Atopic Dermatitis Data Published in the New England Journal of Medicine

    TARRYTOWN, N.Y. and PARIS, Oct. 1, 2016 /PRNewswire/ -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) and Sanofi today announce that detailed results from LIBERTY AD SOLO 1 and SOLO 2, two placebo-controlled Phase 3 studies evaluating investigational Dupixent® (dupilumab) in adult patients with inadequately controlled moderate-to-severe atopic dermatitis (AD), were published in the New England Journal of Medicine (NEJM). In addition, both trials met key secondary endpoints measuring reduction in itch, improvement in patient-reported anxiety and depression symptoms, and certain quality of life measures. Dupixent inhibits signaling of IL-4 and IL-13, two key cytokines required for the type 2 (including Th2) immune response, which is believed to be a major driver in AD, and certain atopic or allergic diseases including asthma and nasal polyposis, where Dupixent is being evaluated in ongoing clinical studies.

  • The Highest-Yielding Drug Stocks
    Motley Fool22 hours ago

    The Highest-Yielding Drug Stocks

    These drug developers are putting shareholders first.